NCT05672147View on ClinicalTrials.gov

CD33-CAR T Cell Therapy for the Treatment of Recurrent or Refractory Acute Myeloid Leukemia

PHASE1RecruitingINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

December 7, 2023

Primary Completion Date

September 3, 2028

Study Completion Date

September 3, 2028

Conditions
Acute Myeloid LeukemiaRecurrent Adult Acute Myeloid LeukemiaRefractory Acute Myeloid LeukemiaSecondary Acute Myeloid Leukemia
Interventions
BIOLOGICAL

Anti-CD33 CAR T-cells

Given IV

PROCEDURE

Lymphodepletion Therapy

Undergo lymphodepletion

Trial Locations (1)

91010

RECRUITING

City of Hope Medical Center, Duarte

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER